XORTX Therapeutics Inc.
Get $10 bonus on your first $100 deposit for XRTX
Get $10 bonus on your first $100 deposit for XRTX
XORTX Therapeutics Inc. (XRTX) Stock Competitors & Peer Comparison
See (XRTX) competitors and their performances in Stock Market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| XRTX | $2.91 | +28.28% | 626.6K | -0.80 | -$2.80 | N/A |
| VRTX | $436.27 | -1.12% | 111.7B | 28.65 | $15.33 | N/A |
| REGN | $739.43 | -1.48% | 77.9B | 17.97 | $41.73 | +0.24% |
| VRNA | $106.91 | +0.11% | 72.7B | -102.80 | -$1.04 | N/A |
| ARGX | $803.91 | -5.32% | 51.6B | 42.55 | $19.61 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| ALNY | $305.23 | -1.43% | 41.2B | 132.88 | $2.34 | N/A |
| INSM | $141.71 | -1.92% | 30.8B | -22.21 | -$6.43 | N/A |
| RVMD | $145.66 | -2.00% | 29B | -24.53 | -$5.96 | N/A |
| BNTX | $110.02 | +6.90% | 26.4B | -18.95 | -$5.55 | N/A |
Stock Comparison
XRTX vs VRTX Comparison April 2026
XRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XRTX stands at 626.6K. In comparison, VRTX has a market cap of 111.7B. Regarding current trading prices, XRTX is priced at $2.91, while VRTX trades at $436.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XRTX currently has a P/E ratio of -0.80, whereas VRTX's P/E ratio is 28.65. In terms of profitability, XRTX's ROE is -1.11%, compared to VRTX's ROE of +0.23%. Regarding short-term risk, XRTX is more volatile compared to VRTX. This indicates potentially higher risk in terms of short-term price fluctuations for XRTX.Check VRTX's competition here
XRTX vs REGN Comparison April 2026
XRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XRTX stands at 626.6K. In comparison, REGN has a market cap of 77.9B. Regarding current trading prices, XRTX is priced at $2.91, while REGN trades at $739.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XRTX currently has a P/E ratio of -0.80, whereas REGN's P/E ratio is 17.97. In terms of profitability, XRTX's ROE is -1.11%, compared to REGN's ROE of +0.15%. Regarding short-term risk, XRTX is more volatile compared to REGN. This indicates potentially higher risk in terms of short-term price fluctuations for XRTX.Check REGN's competition here
XRTX vs VRNA Comparison April 2026
XRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XRTX stands at 626.6K. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, XRTX is priced at $2.91, while VRNA trades at $106.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XRTX currently has a P/E ratio of -0.80, whereas VRNA's P/E ratio is -102.80. In terms of profitability, XRTX's ROE is -1.11%, compared to VRNA's ROE of -0.13%. Regarding short-term risk, XRTX is more volatile compared to VRNA. This indicates potentially higher risk in terms of short-term price fluctuations for XRTX.Check VRNA's competition here
XRTX vs ARGX Comparison April 2026
XRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XRTX stands at 626.6K. In comparison, ARGX has a market cap of 51.6B. Regarding current trading prices, XRTX is priced at $2.91, while ARGX trades at $803.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XRTX currently has a P/E ratio of -0.80, whereas ARGX's P/E ratio is 42.55. In terms of profitability, XRTX's ROE is -1.11%, compared to ARGX's ROE of +0.34%. Regarding short-term risk, XRTX is more volatile compared to ARGX. This indicates potentially higher risk in terms of short-term price fluctuations for XRTX.Check ARGX's competition here
XRTX vs SGEN Comparison April 2026
XRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XRTX stands at 626.6K. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, XRTX is priced at $2.91, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XRTX currently has a P/E ratio of -0.80, whereas SGEN's P/E ratio is -57.19. In terms of profitability, XRTX's ROE is -1.11%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, XRTX is more volatile compared to SGEN. This indicates potentially higher risk in terms of short-term price fluctuations for XRTX.Check SGEN's competition here
XRTX vs ALNY Comparison April 2026
XRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XRTX stands at 626.6K. In comparison, ALNY has a market cap of 41.2B. Regarding current trading prices, XRTX is priced at $2.91, while ALNY trades at $305.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XRTX currently has a P/E ratio of -0.80, whereas ALNY's P/E ratio is 132.88. In terms of profitability, XRTX's ROE is -1.11%, compared to ALNY's ROE of +0.90%. Regarding short-term risk, XRTX is more volatile compared to ALNY. This indicates potentially higher risk in terms of short-term price fluctuations for XRTX.Check ALNY's competition here
XRTX vs INSM Comparison April 2026
XRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XRTX stands at 626.6K. In comparison, INSM has a market cap of 30.8B. Regarding current trading prices, XRTX is priced at $2.91, while INSM trades at $141.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XRTX currently has a P/E ratio of -0.80, whereas INSM's P/E ratio is -22.21. In terms of profitability, XRTX's ROE is -1.11%, compared to INSM's ROE of -1.68%. Regarding short-term risk, XRTX is more volatile compared to INSM. This indicates potentially higher risk in terms of short-term price fluctuations for XRTX.Check INSM's competition here
XRTX vs RVMD Comparison April 2026
XRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XRTX stands at 626.6K. In comparison, RVMD has a market cap of 29B. Regarding current trading prices, XRTX is priced at $2.91, while RVMD trades at $145.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XRTX currently has a P/E ratio of -0.80, whereas RVMD's P/E ratio is -24.53. In terms of profitability, XRTX's ROE is -1.11%, compared to RVMD's ROE of -0.63%. Regarding short-term risk, XRTX is more volatile compared to RVMD. This indicates potentially higher risk in terms of short-term price fluctuations for XRTX.Check RVMD's competition here
XRTX vs BNTX Comparison April 2026
XRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XRTX stands at 626.6K. In comparison, BNTX has a market cap of 26.4B. Regarding current trading prices, XRTX is priced at $2.91, while BNTX trades at $110.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XRTX currently has a P/E ratio of -0.80, whereas BNTX's P/E ratio is -18.95. In terms of profitability, XRTX's ROE is -1.11%, compared to BNTX's ROE of -0.06%. Regarding short-term risk, XRTX is more volatile compared to BNTX. This indicates potentially higher risk in terms of short-term price fluctuations for XRTX.Check BNTX's competition here
XRTX vs UTHR Comparison April 2026
XRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XRTX stands at 626.6K. In comparison, UTHR has a market cap of 25.1B. Regarding current trading prices, XRTX is priced at $2.91, while UTHR trades at $567.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XRTX currently has a P/E ratio of -0.80, whereas UTHR's P/E ratio is 20.57. In terms of profitability, XRTX's ROE is -1.11%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, XRTX is more volatile compared to UTHR. This indicates potentially higher risk in terms of short-term price fluctuations for XRTX.Check UTHR's competition here
XRTX vs MRNA Comparison April 2026
XRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XRTX stands at 626.6K. In comparison, MRNA has a market cap of 21.6B. Regarding current trading prices, XRTX is priced at $2.91, while MRNA trades at $54.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XRTX currently has a P/E ratio of -0.80, whereas MRNA's P/E ratio is -7.52. In terms of profitability, XRTX's ROE is -1.11%, compared to MRNA's ROE of -0.30%. Regarding short-term risk, XRTX is more volatile compared to MRNA. This indicates potentially higher risk in terms of short-term price fluctuations for XRTX.Check MRNA's competition here
XRTX vs RPRX Comparison April 2026
XRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XRTX stands at 626.6K. In comparison, RPRX has a market cap of 21.1B. Regarding current trading prices, XRTX is priced at $2.91, while RPRX trades at $49.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XRTX currently has a P/E ratio of -0.80, whereas RPRX's P/E ratio is 27.70. In terms of profitability, XRTX's ROE is -1.11%, compared to RPRX's ROE of +0.12%. Regarding short-term risk, XRTX is more volatile compared to RPRX. This indicates potentially higher risk in terms of short-term price fluctuations for XRTX.Check RPRX's competition here
XRTX vs ROIV Comparison April 2026
XRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XRTX stands at 626.6K. In comparison, ROIV has a market cap of 20.8B. Regarding current trading prices, XRTX is priced at $2.91, while ROIV trades at $29.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XRTX currently has a P/E ratio of -0.80, whereas ROIV's P/E ratio is -24.85. In terms of profitability, XRTX's ROE is -1.11%, compared to ROIV's ROE of -0.18%. Regarding short-term risk, XRTX is more volatile compared to ROIV. This indicates potentially higher risk in terms of short-term price fluctuations for XRTX.Check ROIV's competition here
XRTX vs BGNE Comparison April 2026
XRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XRTX stands at 626.6K. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, XRTX is priced at $2.91, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XRTX currently has a P/E ratio of -0.80, whereas BGNE's P/E ratio is -22.55. In terms of profitability, XRTX's ROE is -1.11%, compared to BGNE's ROE of +0.07%. Regarding short-term risk, XRTX is more volatile compared to BGNE. This indicates potentially higher risk in terms of short-term price fluctuations for XRTX.Check BGNE's competition here
XRTX vs SMMT Comparison April 2026
XRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XRTX stands at 626.6K. In comparison, SMMT has a market cap of 19.5B. Regarding current trading prices, XRTX is priced at $2.91, while SMMT trades at $26.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XRTX currently has a P/E ratio of -0.80, whereas SMMT's P/E ratio is -17.44. In terms of profitability, XRTX's ROE is -1.11%, compared to SMMT's ROE of -2.97%. Regarding short-term risk, XRTX is more volatile compared to SMMT. This indicates potentially higher risk in terms of short-term price fluctuations for XRTX.Check SMMT's competition here
XRTX vs INCY Comparison April 2026
XRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XRTX stands at 626.6K. In comparison, INCY has a market cap of 19.3B. Regarding current trading prices, XRTX is priced at $2.91, while INCY trades at $96.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XRTX currently has a P/E ratio of -0.80, whereas INCY's P/E ratio is 15.12. In terms of profitability, XRTX's ROE is -1.11%, compared to INCY's ROE of +0.29%. Regarding short-term risk, XRTX is more volatile compared to INCY. This indicates potentially higher risk in terms of short-term price fluctuations for XRTX.Check INCY's competition here
XRTX vs DNA-WT Comparison April 2026
XRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XRTX stands at 626.6K. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, XRTX is priced at $2.91, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XRTX currently has a P/E ratio of -0.80, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, XRTX's ROE is -1.11%, compared to DNA-WT's ROE of -0.54%. Regarding short-term risk, XRTX is more volatile compared to DNA-WT. This indicates potentially higher risk in terms of short-term price fluctuations for XRTX.Check DNA-WT's competition here
XRTX vs GMAB Comparison April 2026
XRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XRTX stands at 626.6K. In comparison, GMAB has a market cap of 17.2B. Regarding current trading prices, XRTX is priced at $2.91, while GMAB trades at $27.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XRTX currently has a P/E ratio of -0.80, whereas GMAB's P/E ratio is 18.12. In terms of profitability, XRTX's ROE is -1.11%, compared to GMAB's ROE of +0.14%. Regarding short-term risk, XRTX is more volatile compared to GMAB. This indicates potentially higher risk in terms of short-term price fluctuations for XRTX.Check GMAB's competition here
XRTX vs ASND Comparison April 2026
XRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XRTX stands at 626.6K. In comparison, ASND has a market cap of 15.1B. Regarding current trading prices, XRTX is priced at $2.91, while ASND trades at $238.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XRTX currently has a P/E ratio of -0.80, whereas ASND's P/E ratio is -55.14. In terms of profitability, XRTX's ROE is -1.11%, compared to ASND's ROE of +1.28%. Regarding short-term risk, XRTX is more volatile compared to ASND. This indicates potentially higher risk in terms of short-term price fluctuations for XRTX.Check ASND's competition here
XRTX vs BBIO Comparison April 2026
XRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XRTX stands at 626.6K. In comparison, BBIO has a market cap of 14.9B. Regarding current trading prices, XRTX is priced at $2.91, while BBIO trades at $75.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XRTX currently has a P/E ratio of -0.80, whereas BBIO's P/E ratio is -20.29. In terms of profitability, XRTX's ROE is -1.11%, compared to BBIO's ROE of +0.39%. Regarding short-term risk, XRTX is more volatile compared to BBIO. This indicates potentially higher risk in terms of short-term price fluctuations for XRTX.Check BBIO's competition here
XRTX vs KRTX Comparison April 2026
XRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XRTX stands at 626.6K. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, XRTX is priced at $2.91, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XRTX currently has a P/E ratio of -0.80, whereas KRTX's P/E ratio is -28.09. In terms of profitability, XRTX's ROE is -1.11%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, XRTX is more volatile compared to KRTX. This indicates potentially higher risk in terms of short-term price fluctuations for XRTX.Check KRTX's competition here
XRTX vs JAZZ Comparison April 2026
XRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XRTX stands at 626.6K. In comparison, JAZZ has a market cap of 12.5B. Regarding current trading prices, XRTX is priced at $2.91, while JAZZ trades at $199.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XRTX currently has a P/E ratio of -0.80, whereas JAZZ's P/E ratio is -34.68. In terms of profitability, XRTX's ROE is -1.11%, compared to JAZZ's ROE of -0.09%. Regarding short-term risk, XRTX is more volatile compared to JAZZ. This indicates potentially higher risk in terms of short-term price fluctuations for XRTX.Check JAZZ's competition here
XRTX vs IONS Comparison April 2026
XRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XRTX stands at 626.6K. In comparison, IONS has a market cap of 12.4B. Regarding current trading prices, XRTX is priced at $2.91, while IONS trades at $73.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XRTX currently has a P/E ratio of -0.80, whereas IONS's P/E ratio is -31.46. In terms of profitability, XRTX's ROE is -1.11%, compared to IONS's ROE of -0.69%. Regarding short-term risk, XRTX is more volatile compared to IONS. This indicates potentially higher risk in terms of short-term price fluctuations for XRTX.Check IONS's competition here
XRTX vs MDGL Comparison April 2026
XRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XRTX stands at 626.6K. In comparison, MDGL has a market cap of 12.1B. Regarding current trading prices, XRTX is priced at $2.91, while MDGL trades at $528.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XRTX currently has a P/E ratio of -0.80, whereas MDGL's P/E ratio is -40.99. In terms of profitability, XRTX's ROE is -1.11%, compared to MDGL's ROE of -0.44%. Regarding short-term risk, XRTX is more volatile compared to MDGL. This indicates potentially higher risk in terms of short-term price fluctuations for XRTX.Check MDGL's competition here
XRTX vs EXEL Comparison April 2026
XRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XRTX stands at 626.6K. In comparison, EXEL has a market cap of 11.3B. Regarding current trading prices, XRTX is priced at $2.91, while EXEL trades at $45.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XRTX currently has a P/E ratio of -0.80, whereas EXEL's P/E ratio is 15.69. In terms of profitability, XRTX's ROE is -1.11%, compared to EXEL's ROE of +0.37%. Regarding short-term risk, XRTX is more volatile compared to EXEL. This indicates potentially higher risk in terms of short-term price fluctuations for XRTX.Check EXEL's competition here
XRTX vs RNAM Comparison April 2026
XRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XRTX stands at 626.6K. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, XRTX is priced at $2.91, while RNAM trades at $72.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XRTX currently has a P/E ratio of -0.80, whereas RNAM's P/E ratio is -17.39. In terms of profitability, XRTX's ROE is -1.11%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, XRTX is more volatile compared to RNAM. This indicates potentially higher risk in terms of short-term price fluctuations for XRTX.Check RNAM's competition here
XRTX vs BMRN Comparison April 2026
XRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XRTX stands at 626.6K. In comparison, BMRN has a market cap of 10.6B. Regarding current trading prices, XRTX is priced at $2.91, while BMRN trades at $54.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XRTX currently has a P/E ratio of -0.80, whereas BMRN's P/E ratio is 30.49. In terms of profitability, XRTX's ROE is -1.11%, compared to BMRN's ROE of +0.06%. Regarding short-term risk, XRTX is more volatile compared to BMRN. This indicates potentially higher risk in terms of short-term price fluctuations for XRTX.Check BMRN's competition here
XRTX vs ARWR Comparison April 2026
XRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XRTX stands at 626.6K. In comparison, ARWR has a market cap of 9.7B. Regarding current trading prices, XRTX is priced at $2.91, while ARWR trades at $71.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XRTX currently has a P/E ratio of -0.80, whereas ARWR's P/E ratio is 43.28. In terms of profitability, XRTX's ROE is -1.11%, compared to ARWR's ROE of +0.36%. Regarding short-term risk, XRTX is more volatile compared to ARWR. This indicates potentially higher risk in terms of short-term price fluctuations for XRTX.Check ARWR's competition here
XRTX vs AXSM Comparison April 2026
XRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XRTX stands at 626.6K. In comparison, AXSM has a market cap of 9.7B. Regarding current trading prices, XRTX is priced at $2.91, while AXSM trades at $184.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XRTX currently has a P/E ratio of -0.80, whereas AXSM's P/E ratio is -51.14. In terms of profitability, XRTX's ROE is -1.11%, compared to AXSM's ROE of -2.54%. Regarding short-term risk, XRTX is more volatile compared to AXSM. This indicates potentially higher risk in terms of short-term price fluctuations for XRTX.Check AXSM's competition here
XRTX vs RXDX Comparison April 2026
XRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XRTX stands at 626.6K. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, XRTX is priced at $2.91, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XRTX currently has a P/E ratio of -0.80, whereas RXDX's P/E ratio is -56.47. In terms of profitability, XRTX's ROE is -1.11%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, XRTX is more volatile compared to RXDX. This indicates potentially higher risk in terms of short-term price fluctuations for XRTX.Check RXDX's competition here
XRTX vs TECH Comparison April 2026
XRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XRTX stands at 626.6K. In comparison, TECH has a market cap of 9.5B. Regarding current trading prices, XRTX is priced at $2.91, while TECH trades at $60.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XRTX currently has a P/E ratio of -0.80, whereas TECH's P/E ratio is 112.19. In terms of profitability, XRTX's ROE is -1.11%, compared to TECH's ROE of +0.04%. Regarding short-term risk, XRTX is more volatile compared to TECH. This indicates potentially higher risk in terms of short-term price fluctuations for XRTX.Check TECH's competition here
XRTX vs PCVX Comparison April 2026
XRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XRTX stands at 626.6K. In comparison, PCVX has a market cap of 8.9B. Regarding current trading prices, XRTX is priced at $2.91, while PCVX trades at $61.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XRTX currently has a P/E ratio of -0.80, whereas PCVX's P/E ratio is -11.01. In terms of profitability, XRTX's ROE is -1.11%, compared to PCVX's ROE of -0.26%. Regarding short-term risk, XRTX is more volatile compared to PCVX. This indicates potentially higher risk in terms of short-term price fluctuations for XRTX.Check PCVX's competition here
XRTX vs IMGN Comparison April 2026
XRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XRTX stands at 626.6K. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, XRTX is priced at $2.91, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XRTX currently has a P/E ratio of -0.80, whereas IMGN's P/E ratio is -111.55. In terms of profitability, XRTX's ROE is -1.11%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, XRTX is more volatile compared to IMGN. This indicates potentially higher risk in terms of short-term price fluctuations for XRTX.Check IMGN's competition here
XRTX vs IBRX Comparison April 2026
XRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XRTX stands at 626.6K. In comparison, IBRX has a market cap of 8.4B. Regarding current trading prices, XRTX is priced at $2.91, while IBRX trades at $8.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XRTX currently has a P/E ratio of -0.80, whereas IBRX's P/E ratio is -21.58. In terms of profitability, XRTX's ROE is -1.11%, compared to IBRX's ROE of +0.64%. Regarding short-term risk, XRTX is more volatile compared to IBRX. This indicates potentially higher risk in terms of short-term price fluctuations for XRTX.Check IBRX's competition here
XRTX vs BPMC Comparison April 2026
XRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XRTX stands at 626.6K. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, XRTX is priced at $2.91, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XRTX currently has a P/E ratio of -0.80, whereas BPMC's P/E ratio is -51.58. In terms of profitability, XRTX's ROE is -1.11%, compared to BPMC's ROE of -0.15%. Regarding short-term risk, XRTX is more volatile compared to BPMC. This indicates potentially higher risk in terms of short-term price fluctuations for XRTX.Check BPMC's competition here
XRTX vs HALO Comparison April 2026
XRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XRTX stands at 626.6K. In comparison, HALO has a market cap of 8.2B. Regarding current trading prices, XRTX is priced at $2.91, while HALO trades at $69.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XRTX currently has a P/E ratio of -0.80, whereas HALO's P/E ratio is 27.18. In terms of profitability, XRTX's ROE is -1.11%, compared to HALO's ROE of +0.93%. Regarding short-term risk, XRTX is more volatile compared to HALO. This indicates potentially higher risk in terms of short-term price fluctuations for XRTX.Check HALO's competition here
XRTX vs CERE Comparison April 2026
XRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XRTX stands at 626.6K. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, XRTX is priced at $2.91, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XRTX currently has a P/E ratio of -0.80, whereas CERE's P/E ratio is -16.47. In terms of profitability, XRTX's ROE is -1.11%, compared to CERE's ROE of -0.72%. Regarding short-term risk, XRTX is more volatile compared to CERE. This indicates potentially higher risk in terms of short-term price fluctuations for XRTX.Check CERE's competition here
XRTX vs CYTK Comparison April 2026
XRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XRTX stands at 626.6K. In comparison, CYTK has a market cap of 8.1B. Regarding current trading prices, XRTX is priced at $2.91, while CYTK trades at $65.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XRTX currently has a P/E ratio of -0.80, whereas CYTK's P/E ratio is -10.11. In terms of profitability, XRTX's ROE is -1.11%, compared to CYTK's ROE of +1.73%. Regarding short-term risk, XRTX is more volatile compared to CYTK. This indicates potentially higher risk in terms of short-term price fluctuations for XRTX.Check CYTK's competition here
XRTX vs KRYS Comparison April 2026
XRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XRTX stands at 626.6K. In comparison, KRYS has a market cap of 8.1B. Regarding current trading prices, XRTX is priced at $2.91, while KRYS trades at $274.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XRTX currently has a P/E ratio of -0.80, whereas KRYS's P/E ratio is 40.48. In terms of profitability, XRTX's ROE is -1.11%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, XRTX is more volatile compared to KRYS. This indicates potentially higher risk in terms of short-term price fluctuations for XRTX.Check KRYS's competition here
XRTX vs NUVL Comparison April 2026
XRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XRTX stands at 626.6K. In comparison, NUVL has a market cap of 7.9B. Regarding current trading prices, XRTX is priced at $2.91, while NUVL trades at $106.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XRTX currently has a P/E ratio of -0.80, whereas NUVL's P/E ratio is -18.50. In terms of profitability, XRTX's ROE is -1.11%, compared to NUVL's ROE of -0.42%. Regarding short-term risk, XRTX is more volatile compared to NUVL. This indicates potentially higher risk in terms of short-term price fluctuations for XRTX.Check NUVL's competition here
XRTX vs ABVX Comparison April 2026
XRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XRTX stands at 626.6K. In comparison, ABVX has a market cap of 7.5B. Regarding current trading prices, XRTX is priced at $2.91, while ABVX trades at $114.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XRTX currently has a P/E ratio of -0.80, whereas ABVX's P/E ratio is -20.14. In terms of profitability, XRTX's ROE is -1.11%, compared to ABVX's ROE of -1.59%. Regarding short-term risk, XRTX is more volatile compared to ABVX. This indicates potentially higher risk in terms of short-term price fluctuations for XRTX.Check ABVX's competition here
XRTX vs MTSR Comparison April 2026
XRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XRTX stands at 626.6K. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, XRTX is priced at $2.91, while MTSR trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XRTX currently has a P/E ratio of -0.80, whereas MTSR's P/E ratio is -23.58. In terms of profitability, XRTX's ROE is -1.11%, compared to MTSR's ROE of -0.80%. Regarding short-term risk, XRTX is more volatile compared to MTSR. This indicates potentially higher risk in terms of short-term price fluctuations for XRTX.Check MTSR's competition here
XRTX vs PRAX Comparison April 2026
XRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XRTX stands at 626.6K. In comparison, PRAX has a market cap of 7.2B. Regarding current trading prices, XRTX is priced at $2.91, while PRAX trades at $335.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XRTX currently has a P/E ratio of -0.80, whereas PRAX's P/E ratio is -25.43. In terms of profitability, XRTX's ROE is -1.11%, compared to PRAX's ROE of -0.59%. Regarding short-term risk, XRTX is more volatile compared to PRAX. This indicates potentially higher risk in terms of short-term price fluctuations for XRTX.Check PRAX's competition here
XRTX vs KYMR Comparison April 2026
XRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XRTX stands at 626.6K. In comparison, KYMR has a market cap of 7.1B. Regarding current trading prices, XRTX is priced at $2.91, while KYMR trades at $86.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XRTX currently has a P/E ratio of -0.80, whereas KYMR's P/E ratio is -23.56. In terms of profitability, XRTX's ROE is -1.11%, compared to KYMR's ROE of -0.29%. Regarding short-term risk, XRTX is more volatile compared to KYMR. This indicates potentially higher risk in terms of short-term price fluctuations for XRTX.Check KYMR's competition here
XRTX vs MRUS Comparison April 2026
XRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XRTX stands at 626.6K. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, XRTX is priced at $2.91, while MRUS trades at $90.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XRTX currently has a P/E ratio of -0.80, whereas MRUS's P/E ratio is -17.05. In terms of profitability, XRTX's ROE is -1.11%, compared to MRUS's ROE of -0.51%. Regarding short-term risk, XRTX is more volatile compared to MRUS. This indicates potentially higher risk in terms of short-term price fluctuations for XRTX.Check MRUS's competition here
XRTX vs ERAS Comparison April 2026
XRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XRTX stands at 626.6K. In comparison, ERAS has a market cap of 6.7B. Regarding current trading prices, XRTX is priced at $2.91, while ERAS trades at $21.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XRTX currently has a P/E ratio of -0.80, whereas ERAS's P/E ratio is -49.34. In terms of profitability, XRTX's ROE is -1.11%, compared to ERAS's ROE of -0.34%. Regarding short-term risk, XRTX is more volatile compared to ERAS. This indicates potentially higher risk in terms of short-term price fluctuations for XRTX.Check ERAS's competition here
XRTX vs PTGX Comparison April 2026
XRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XRTX stands at 626.6K. In comparison, PTGX has a market cap of 6.7B. Regarding current trading prices, XRTX is priced at $2.91, while PTGX trades at $104.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XRTX currently has a P/E ratio of -0.80, whereas PTGX's P/E ratio is -51.45. In terms of profitability, XRTX's ROE is -1.11%, compared to PTGX's ROE of -0.20%. Regarding short-term risk, XRTX is more volatile compared to PTGX. This indicates potentially higher risk in terms of short-term price fluctuations for XRTX.Check PTGX's competition here
XRTX vs ACLX Comparison April 2026
XRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XRTX stands at 626.6K. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, XRTX is priced at $2.91, while ACLX trades at $115.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XRTX currently has a P/E ratio of -0.80, whereas ACLX's P/E ratio is -28.26. In terms of profitability, XRTX's ROE is -1.11%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, XRTX is more volatile compared to ACLX. This indicates potentially higher risk in terms of short-term price fluctuations for XRTX.Check ACLX's competition here
XRTX vs BLTE Comparison April 2026
XRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XRTX stands at 626.6K. In comparison, BLTE has a market cap of 6.6B. Regarding current trading prices, XRTX is priced at $2.91, while BLTE trades at $165.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XRTX currently has a P/E ratio of -0.80, whereas BLTE's P/E ratio is -71.31. In terms of profitability, XRTX's ROE is -1.11%, compared to BLTE's ROE of -0.23%. Regarding short-term risk, XRTX is more volatile compared to BLTE. This indicates potentially higher risk in terms of short-term price fluctuations for XRTX.Check BLTE's competition here
XRTX vs RETA Comparison April 2026
XRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XRTX stands at 626.6K. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, XRTX is priced at $2.91, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XRTX currently has a P/E ratio of -0.80, whereas RETA's P/E ratio is -66.29. In terms of profitability, XRTX's ROE is -1.11%, compared to RETA's ROE of +0.47%. Regarding short-term risk, XRTX is more volatile compared to RETA. This indicates potentially higher risk in terms of short-term price fluctuations for XRTX.Check RETA's competition here
XRTX vs COGT Comparison April 2026
XRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XRTX stands at 626.6K. In comparison, COGT has a market cap of 6B. Regarding current trading prices, XRTX is priced at $2.91, while COGT trades at $37.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XRTX currently has a P/E ratio of -0.80, whereas COGT's P/E ratio is -17.13. In terms of profitability, XRTX's ROE is -1.11%, compared to COGT's ROE of -1.00%. Regarding short-term risk, XRTX is more volatile compared to COGT. This indicates potentially higher risk in terms of short-term price fluctuations for XRTX.Check COGT's competition here
XRTX vs CAI Comparison April 2026
XRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XRTX stands at 626.6K. In comparison, CAI has a market cap of 6B. Regarding current trading prices, XRTX is priced at $2.91, while CAI trades at $21.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XRTX currently has a P/E ratio of -0.80, whereas CAI's P/E ratio is -6.60. In terms of profitability, XRTX's ROE is -1.11%, compared to CAI's ROE of +0.25%. Regarding short-term risk, XRTX is more volatile compared to CAI. This indicates potentially higher risk in terms of short-term price fluctuations for XRTX.Check CAI's competition here
XRTX vs RYTM Comparison April 2026
XRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XRTX stands at 626.6K. In comparison, RYTM has a market cap of 6B. Regarding current trading prices, XRTX is priced at $2.91, while RYTM trades at $85.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XRTX currently has a P/E ratio of -0.80, whereas RYTM's P/E ratio is -28.21. In terms of profitability, XRTX's ROE is -1.11%, compared to RYTM's ROE of -1.79%. Regarding short-term risk, XRTX is more volatile compared to RYTM. This indicates potentially higher risk in terms of short-term price fluctuations for XRTX.Check RYTM's competition here
XRTX vs PTCT Comparison April 2026
XRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XRTX stands at 626.6K. In comparison, PTCT has a market cap of 6B. Regarding current trading prices, XRTX is priced at $2.91, while PTCT trades at $71.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XRTX currently has a P/E ratio of -0.80, whereas PTCT's P/E ratio is 8.43. In terms of profitability, XRTX's ROE is -1.11%, compared to PTCT's ROE of -3.62%. Regarding short-term risk, XRTX is more volatile compared to PTCT. This indicates potentially higher risk in terms of short-term price fluctuations for XRTX.Check PTCT's competition here
XRTX vs CGON Comparison April 2026
XRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XRTX stands at 626.6K. In comparison, CGON has a market cap of 5.9B. Regarding current trading prices, XRTX is priced at $2.91, while CGON trades at $71.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XRTX currently has a P/E ratio of -0.80, whereas CGON's P/E ratio is -33.85. In terms of profitability, XRTX's ROE is -1.11%, compared to CGON's ROE of -0.23%. Regarding short-term risk, XRTX is more volatile compared to CGON. This indicates potentially higher risk in terms of short-term price fluctuations for XRTX.Check CGON's competition here
XRTX vs TGTX Comparison April 2026
XRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XRTX stands at 626.6K. In comparison, TGTX has a market cap of 5.9B. Regarding current trading prices, XRTX is priced at $2.91, while TGTX trades at $36.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XRTX currently has a P/E ratio of -0.80, whereas TGTX's P/E ratio is 13.34. In terms of profitability, XRTX's ROE is -1.11%, compared to TGTX's ROE of +1.01%. Regarding short-term risk, XRTX is more volatile compared to TGTX. This indicates potentially higher risk in terms of short-term price fluctuations for XRTX.Check TGTX's competition here
XRTX vs CNTA Comparison April 2026
XRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XRTX stands at 626.6K. In comparison, CNTA has a market cap of 5.9B. Regarding current trading prices, XRTX is priced at $2.91, while CNTA trades at $39.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XRTX currently has a P/E ratio of -0.80, whereas CNTA's P/E ratio is -27.06. In terms of profitability, XRTX's ROE is -1.11%, compared to CNTA's ROE of -0.51%. Regarding short-term risk, XRTX is more volatile compared to CNTA. This indicates potentially higher risk in terms of short-term price fluctuations for XRTX.Check CNTA's competition here
XRTX vs IMVT Comparison April 2026
XRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XRTX stands at 626.6K. In comparison, IMVT has a market cap of 5.8B. Regarding current trading prices, XRTX is priced at $2.91, while IMVT trades at $28.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XRTX currently has a P/E ratio of -0.80, whereas IMVT's P/E ratio is -10.69. In terms of profitability, XRTX's ROE is -1.11%, compared to IMVT's ROE of -0.66%. Regarding short-term risk, XRTX is more volatile compared to IMVT. This indicates potentially higher risk in terms of short-term price fluctuations for XRTX.Check IMVT's competition here
XRTX vs CELC Comparison April 2026
XRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XRTX stands at 626.6K. In comparison, CELC has a market cap of 5.8B. Regarding current trading prices, XRTX is priced at $2.91, while CELC trades at $119.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XRTX currently has a P/E ratio of -0.80, whereas CELC's P/E ratio is -31.60. In terms of profitability, XRTX's ROE is -1.11%, compared to CELC's ROE of -2.03%. Regarding short-term risk, XRTX is more volatile compared to CELC. This indicates potentially higher risk in terms of short-term price fluctuations for XRTX.Check CELC's competition here
XRTX vs ALKS Comparison April 2026
XRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XRTX stands at 626.6K. In comparison, ALKS has a market cap of 5.7B. Regarding current trading prices, XRTX is priced at $2.91, while ALKS trades at $33.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XRTX currently has a P/E ratio of -0.80, whereas ALKS's P/E ratio is 23.94. In terms of profitability, XRTX's ROE is -1.11%, compared to ALKS's ROE of +0.14%. Regarding short-term risk, XRTX is more volatile compared to ALKS. This indicates potentially higher risk in terms of short-term price fluctuations for XRTX.Check ALKS's competition here
XRTX vs CDTX Comparison April 2026
XRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XRTX stands at 626.6K. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, XRTX is priced at $2.91, while CDTX trades at $221.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XRTX currently has a P/E ratio of -0.80, whereas CDTX's P/E ratio is -19.77. In terms of profitability, XRTX's ROE is -1.11%, compared to CDTX's ROE of -0.60%. Regarding short-term risk, XRTX is more volatile compared to CDTX. This indicates potentially higher risk in terms of short-term price fluctuations for XRTX.Check CDTX's competition here
XRTX vs CRSP Comparison April 2026
XRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XRTX stands at 626.6K. In comparison, CRSP has a market cap of 5.5B. Regarding current trading prices, XRTX is priced at $2.91, while CRSP trades at $57.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XRTX currently has a P/E ratio of -0.80, whereas CRSP's P/E ratio is -8.92. In terms of profitability, XRTX's ROE is -1.11%, compared to CRSP's ROE of -0.32%. Regarding short-term risk, XRTX is more volatile compared to CRSP. This indicates potentially higher risk in terms of short-term price fluctuations for XRTX.Check CRSP's competition here
XRTX vs ABCM Comparison April 2026
XRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XRTX stands at 626.6K. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, XRTX is priced at $2.91, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XRTX currently has a P/E ratio of -0.80, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, XRTX's ROE is -1.11%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, XRTX is more volatile compared to ABCM. This indicates potentially higher risk in terms of short-term price fluctuations for XRTX.Check ABCM's competition here
XRTX vs ISEE Comparison April 2026
XRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XRTX stands at 626.6K. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, XRTX is priced at $2.91, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XRTX currently has a P/E ratio of -0.80, whereas ISEE's P/E ratio is -22.44. In terms of profitability, XRTX's ROE is -1.11%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, XRTX is more volatile compared to ISEE. This indicates potentially higher risk in terms of short-term price fluctuations for XRTX.Check ISEE's competition here
XRTX vs SRRK Comparison April 2026
XRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XRTX stands at 626.6K. In comparison, SRRK has a market cap of 5.5B. Regarding current trading prices, XRTX is priced at $2.91, while SRRK trades at $47.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XRTX currently has a P/E ratio of -0.80, whereas SRRK's P/E ratio is -14.53. In terms of profitability, XRTX's ROE is -1.11%, compared to SRRK's ROE of -1.46%. Regarding short-term risk, XRTX is more volatile compared to SRRK. This indicates potentially higher risk in terms of short-term price fluctuations for XRTX.Check SRRK's competition here
XRTX vs FBIOX Comparison April 2026
XRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XRTX stands at 626.6K. In comparison, FBIOX has a market cap of 5.3B. Regarding current trading prices, XRTX is priced at $2.91, while FBIOX trades at $25.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XRTX currently has a P/E ratio of -0.80, whereas FBIOX's P/E ratio is N/A. In terms of profitability, XRTX's ROE is -1.11%, compared to FBIOX's ROE of +0.00%. Regarding short-term risk, XRTX is more volatile compared to FBIOX. This indicates potentially higher risk in terms of short-term price fluctuations for XRTX.Check FBIOX's competition here
XRTX vs APLS Comparison April 2026
XRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XRTX stands at 626.6K. In comparison, APLS has a market cap of 5.2B. Regarding current trading prices, XRTX is priced at $2.91, while APLS trades at $40.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XRTX currently has a P/E ratio of -0.80, whereas APLS's P/E ratio is 227.44. In terms of profitability, XRTX's ROE is -1.11%, compared to APLS's ROE of +0.08%. Regarding short-term risk, XRTX is more volatile compared to APLS. This indicates potentially higher risk in terms of short-term price fluctuations for XRTX.Check APLS's competition here
XRTX vs APGE Comparison April 2026
XRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XRTX stands at 626.6K. In comparison, APGE has a market cap of 5.1B. Regarding current trading prices, XRTX is priced at $2.91, while APGE trades at $90.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XRTX currently has a P/E ratio of -0.80, whereas APGE's P/E ratio is -21.55. In terms of profitability, XRTX's ROE is -1.11%, compared to APGE's ROE of -0.37%. Regarding short-term risk, XRTX is more volatile compared to APGE. This indicates potentially higher risk in terms of short-term price fluctuations for XRTX.Check APGE's competition here
XRTX vs CORT Comparison April 2026
XRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XRTX stands at 626.6K. In comparison, CORT has a market cap of 4.9B. Regarding current trading prices, XRTX is priced at $2.91, while CORT trades at $45.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XRTX currently has a P/E ratio of -0.80, whereas CORT's P/E ratio is 56.51. In terms of profitability, XRTX's ROE is -1.11%, compared to CORT's ROE of +0.15%. Regarding short-term risk, XRTX is more volatile compared to CORT. This indicates potentially higher risk in terms of short-term price fluctuations for XRTX.Check CORT's competition here
XRTX vs MIRM Comparison April 2026
XRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XRTX stands at 626.6K. In comparison, MIRM has a market cap of 4.8B. Regarding current trading prices, XRTX is priced at $2.91, while MIRM trades at $93.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XRTX currently has a P/E ratio of -0.80, whereas MIRM's P/E ratio is -203.64. In terms of profitability, XRTX's ROE is -1.11%, compared to MIRM's ROE of -0.09%. Regarding short-term risk, XRTX is more volatile compared to MIRM. This indicates potentially higher risk in terms of short-term price fluctuations for XRTX.Check MIRM's competition here
XRTX vs TERN Comparison April 2026
XRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XRTX stands at 626.6K. In comparison, TERN has a market cap of 4.8B. Regarding current trading prices, XRTX is priced at $2.91, while TERN trades at $52.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XRTX currently has a P/E ratio of -0.80, whereas TERN's P/E ratio is -51.20. In terms of profitability, XRTX's ROE is -1.11%, compared to TERN's ROE of -0.20%. Regarding short-term risk, XRTX is more volatile compared to TERN. This indicates potentially higher risk in terms of short-term price fluctuations for XRTX.Check TERN's competition here
XRTX vs LEGN Comparison April 2026
XRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XRTX stands at 626.6K. In comparison, LEGN has a market cap of 4.6B. Regarding current trading prices, XRTX is priced at $2.91, while LEGN trades at $25.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XRTX currently has a P/E ratio of -0.80, whereas LEGN's P/E ratio is -15.48. In terms of profitability, XRTX's ROE is -1.11%, compared to LEGN's ROE of -0.29%. Regarding short-term risk, XRTX is more volatile compared to LEGN. This indicates potentially higher risk in terms of short-term price fluctuations for XRTX.Check LEGN's competition here
XRTX vs LGND Comparison April 2026
XRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XRTX stands at 626.6K. In comparison, LGND has a market cap of 4.6B. Regarding current trading prices, XRTX is priced at $2.91, while LGND trades at $225.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XRTX currently has a P/E ratio of -0.80, whereas LGND's P/E ratio is 37.81. In terms of profitability, XRTX's ROE is -1.11%, compared to LGND's ROE of +0.14%. Regarding short-term risk, XRTX is more volatile compared to LGND. This indicates potentially higher risk in terms of short-term price fluctuations for XRTX.Check LGND's competition here
XRTX vs FOLD Comparison April 2026
XRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XRTX stands at 626.6K. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, XRTX is priced at $2.91, while FOLD trades at $14.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XRTX currently has a P/E ratio of -0.80, whereas FOLD's P/E ratio is -160.67. In terms of profitability, XRTX's ROE is -1.11%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, XRTX is more volatile compared to FOLD. This indicates potentially higher risk in terms of short-term price fluctuations for XRTX.Check FOLD's competition here
XRTX vs XENE Comparison April 2026
XRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XRTX stands at 626.6K. In comparison, XENE has a market cap of 4.5B. Regarding current trading prices, XRTX is priced at $2.91, while XENE trades at $56.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XRTX currently has a P/E ratio of -0.80, whereas XENE's P/E ratio is -13.09. In terms of profitability, XRTX's ROE is -1.11%, compared to XENE's ROE of -0.56%. Regarding short-term risk, XRTX is more volatile compared to XENE. This indicates potentially higher risk in terms of short-term price fluctuations for XRTX.Check XENE's competition here
XRTX vs AKRO Comparison April 2026
XRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XRTX stands at 626.6K. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, XRTX is priced at $2.91, while AKRO trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XRTX currently has a P/E ratio of -0.80, whereas AKRO's P/E ratio is -14.57. In terms of profitability, XRTX's ROE is -1.11%, compared to AKRO's ROE of -0.31%. Regarding short-term risk, XRTX is more volatile compared to AKRO. This indicates potentially higher risk in terms of short-term price fluctuations for XRTX.Check AKRO's competition here
XRTX vs ALPN Comparison April 2026
XRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XRTX stands at 626.6K. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, XRTX is priced at $2.91, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XRTX currently has a P/E ratio of -0.80, whereas ALPN's P/E ratio is -101.52. In terms of profitability, XRTX's ROE is -1.11%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, XRTX is more volatile compared to ALPN. This indicates potentially higher risk in terms of short-term price fluctuations for XRTX.Check ALPN's competition here
XRTX vs SYRE Comparison April 2026
XRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XRTX stands at 626.6K. In comparison, SYRE has a market cap of 4.4B. Regarding current trading prices, XRTX is priced at $2.91, while SYRE trades at $71.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XRTX currently has a P/E ratio of -0.80, whereas SYRE's P/E ratio is -37.07. In terms of profitability, XRTX's ROE is -1.11%, compared to SYRE's ROE of -0.29%. Regarding short-term risk, XRTX is more volatile compared to SYRE. This indicates potentially higher risk in terms of short-term price fluctuations for XRTX.Check SYRE's competition here
XRTX vs OPT Comparison April 2026
XRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XRTX stands at 626.6K. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, XRTX is priced at $2.91, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XRTX currently has a P/E ratio of -0.80, whereas OPT's P/E ratio is -1.52. In terms of profitability, XRTX's ROE is -1.11%, compared to OPT's ROE of +0.88%. Regarding short-term risk, XRTX is more volatile compared to OPT. This indicates potentially higher risk in terms of short-term price fluctuations for XRTX.Check OPT's competition here
XRTX vs CRNX Comparison April 2026
XRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XRTX stands at 626.6K. In comparison, CRNX has a market cap of 4.2B. Regarding current trading prices, XRTX is priced at $2.91, while CRNX trades at $39.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XRTX currently has a P/E ratio of -0.80, whereas CRNX's P/E ratio is -8.13. In terms of profitability, XRTX's ROE is -1.11%, compared to CRNX's ROE of -0.41%. Regarding short-term risk, XRTX is more volatile compared to CRNX. This indicates potentially higher risk in terms of short-term price fluctuations for XRTX.Check CRNX's competition here
XRTX vs VKTX Comparison April 2026
XRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XRTX stands at 626.6K. In comparison, VKTX has a market cap of 4.1B. Regarding current trading prices, XRTX is priced at $2.91, while VKTX trades at $33.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XRTX currently has a P/E ratio of -0.80, whereas VKTX's P/E ratio is -11.14. In terms of profitability, XRTX's ROE is -1.11%, compared to VKTX's ROE of -0.48%. Regarding short-term risk, XRTX is more volatile compared to VKTX. This indicates potentially higher risk in terms of short-term price fluctuations for XRTX.Check VKTX's competition here
XRTX vs MRTX Comparison April 2026
XRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XRTX stands at 626.6K. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, XRTX is priced at $2.91, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XRTX currently has a P/E ratio of -0.80, whereas MRTX's P/E ratio is -4.82. In terms of profitability, XRTX's ROE is -1.11%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, XRTX is more volatile compared to MRTX. This indicates potentially higher risk in terms of short-term price fluctuations for XRTX.Check MRTX's competition here
XRTX vs NAMS Comparison April 2026
XRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XRTX stands at 626.6K. In comparison, NAMS has a market cap of 3.9B. Regarding current trading prices, XRTX is priced at $2.91, while NAMS trades at $32.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XRTX currently has a P/E ratio of -0.80, whereas NAMS's P/E ratio is -19.65. In terms of profitability, XRTX's ROE is -1.11%, compared to NAMS's ROE of -0.27%. Regarding short-term risk, XRTX is more volatile compared to NAMS. This indicates potentially higher risk in terms of short-term price fluctuations for XRTX.Check NAMS's competition here
XRTX vs ACAD Comparison April 2026
XRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XRTX stands at 626.6K. In comparison, ACAD has a market cap of 3.8B. Regarding current trading prices, XRTX is priced at $2.91, while ACAD trades at $21.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XRTX currently has a P/E ratio of -0.80, whereas ACAD's P/E ratio is 9.60. In terms of profitability, XRTX's ROE is -1.11%, compared to ACAD's ROE of +0.42%. Regarding short-term risk, XRTX is more volatile compared to ACAD. This indicates potentially higher risk in terms of short-term price fluctuations for XRTX.Check ACAD's competition here
XRTX vs RYZB Comparison April 2026
XRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XRTX stands at 626.6K. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, XRTX is priced at $2.91, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XRTX currently has a P/E ratio of -0.80, whereas RYZB's P/E ratio is -57.86. In terms of profitability, XRTX's ROE is -1.11%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, XRTX is more volatile compared to RYZB. This indicates potentially higher risk in terms of short-term price fluctuations for XRTX.Check RYZB's competition here
XRTX vs CBAY Comparison April 2026
XRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XRTX stands at 626.6K. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, XRTX is priced at $2.91, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XRTX currently has a P/E ratio of -0.80, whereas CBAY's P/E ratio is -32.81. In terms of profitability, XRTX's ROE is -1.11%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, XRTX is more volatile compared to CBAY. This indicates potentially higher risk in terms of short-term price fluctuations for XRTX.Check CBAY's competition here
XRTX vs TVTX Comparison April 2026
XRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XRTX stands at 626.6K. In comparison, TVTX has a market cap of 3.7B. Regarding current trading prices, XRTX is priced at $2.91, while TVTX trades at $38.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XRTX currently has a P/E ratio of -0.80, whereas TVTX's P/E ratio is -70.68. In terms of profitability, XRTX's ROE is -1.11%, compared to TVTX's ROE of -0.79%. Regarding short-term risk, XRTX is more volatile compared to TVTX. This indicates potentially higher risk in terms of short-term price fluctuations for XRTX.Check TVTX's competition here
XRTX vs EWTX Comparison April 2026
XRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XRTX stands at 626.6K. In comparison, EWTX has a market cap of 3.6B. Regarding current trading prices, XRTX is priced at $2.91, while EWTX trades at $32.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XRTX currently has a P/E ratio of -0.80, whereas EWTX's P/E ratio is -20.84. In terms of profitability, XRTX's ROE is -1.11%, compared to EWTX's ROE of -0.32%. Regarding short-term risk, XRTX is more volatile compared to EWTX. This indicates potentially higher risk in terms of short-term price fluctuations for XRTX.Check EWTX's competition here
XRTX vs TLX Comparison April 2026
XRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XRTX stands at 626.6K. In comparison, TLX has a market cap of 3.6B. Regarding current trading prices, XRTX is priced at $2.91, while TLX trades at $10.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XRTX currently has a P/E ratio of -0.80, whereas TLX's P/E ratio is -536.50. In terms of profitability, XRTX's ROE is -1.11%, compared to TLX's ROE of -0.02%. Regarding short-term risk, XRTX is more volatile compared to TLX. This indicates potentially higher risk in terms of short-term price fluctuations for XRTX.Check TLX's competition here
XRTX vs SWTX Comparison April 2026
XRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XRTX stands at 626.6K. In comparison, SWTX has a market cap of 3.5B. Regarding current trading prices, XRTX is priced at $2.91, while SWTX trades at $46.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XRTX currently has a P/E ratio of -0.80, whereas SWTX's P/E ratio is -13.78. In terms of profitability, XRTX's ROE is -1.11%, compared to SWTX's ROE of -0.36%. Regarding short-term risk, XRTX is more volatile compared to SWTX. This indicates potentially higher risk in terms of short-term price fluctuations for XRTX.Check SWTX's competition here
XRTX vs DNTH Comparison April 2026
XRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XRTX stands at 626.6K. In comparison, DNTH has a market cap of 3.5B. Regarding current trading prices, XRTX is priced at $2.91, while DNTH trades at $91.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XRTX currently has a P/E ratio of -0.80, whereas DNTH's P/E ratio is -21.89. In terms of profitability, XRTX's ROE is -1.11%, compared to DNTH's ROE of +0.00%. Regarding short-term risk, XRTX is more volatile compared to DNTH. This indicates potentially higher risk in terms of short-term price fluctuations for XRTX.Check DNTH's competition here
XRTX vs LQDA Comparison April 2026
XRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XRTX stands at 626.6K. In comparison, LQDA has a market cap of 3.3B. Regarding current trading prices, XRTX is priced at $2.91, while LQDA trades at $37.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XRTX currently has a P/E ratio of -0.80, whereas LQDA's P/E ratio is -47.07. In terms of profitability, XRTX's ROE is -1.11%, compared to LQDA's ROE of -2.09%. Regarding short-term risk, XRTX is more volatile compared to LQDA. This indicates potentially higher risk in terms of short-term price fluctuations for XRTX.Check LQDA's competition here
XRTX vs DYN Comparison April 2026
XRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XRTX stands at 626.6K. In comparison, DYN has a market cap of 3.3B. Regarding current trading prices, XRTX is priced at $2.91, while DYN trades at $19.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XRTX currently has a P/E ratio of -0.80, whereas DYN's P/E ratio is -5.77. In terms of profitability, XRTX's ROE is -1.11%, compared to DYN's ROE of -0.61%. Regarding short-term risk, XRTX is more volatile compared to DYN. This indicates potentially higher risk in terms of short-term price fluctuations for XRTX.Check DYN's competition here
XRTX vs DNLI Comparison April 2026
XRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XRTX stands at 626.6K. In comparison, DNLI has a market cap of 3.3B. Regarding current trading prices, XRTX is priced at $2.91, while DNLI trades at $20.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XRTX currently has a P/E ratio of -0.80, whereas DNLI's P/E ratio is -6.92. In terms of profitability, XRTX's ROE is -1.11%, compared to DNLI's ROE of -0.50%. Regarding short-term risk, XRTX is more volatile compared to DNLI. This indicates potentially higher risk in terms of short-term price fluctuations for XRTX.Check DNLI's competition here
XRTX vs CPRX Comparison April 2026
XRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XRTX stands at 626.6K. In comparison, CPRX has a market cap of 3.2B. Regarding current trading prices, XRTX is priced at $2.91, while CPRX trades at $25.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XRTX currently has a P/E ratio of -0.80, whereas CPRX's P/E ratio is 15.34. In terms of profitability, XRTX's ROE is -1.11%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, XRTX is more volatile compared to CPRX. This indicates potentially higher risk in terms of short-term price fluctuations for XRTX.Check CPRX's competition here
XRTX vs BEAM Comparison April 2026
XRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XRTX stands at 626.6K. In comparison, BEAM has a market cap of 3.2B. Regarding current trading prices, XRTX is priced at $2.91, while BEAM trades at $30.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XRTX currently has a P/E ratio of -0.80, whereas BEAM's P/E ratio is -38.51. In terms of profitability, XRTX's ROE is -1.11%, compared to BEAM's ROE of -0.07%. Regarding short-term risk, XRTX is more volatile compared to BEAM. This indicates potentially higher risk in terms of short-term price fluctuations for XRTX.Check BEAM's competition here
XRTX vs KNSA Comparison April 2026
XRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XRTX stands at 626.6K. In comparison, KNSA has a market cap of 3.2B. Regarding current trading prices, XRTX is priced at $2.91, while KNSA trades at $42.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XRTX currently has a P/E ratio of -0.80, whereas KNSA's P/E ratio is 56.61. In terms of profitability, XRTX's ROE is -1.11%, compared to KNSA's ROE of +0.11%. Regarding short-term risk, XRTX is more volatile compared to KNSA. This indicates potentially higher risk in terms of short-term price fluctuations for XRTX.Check KNSA's competition here
XRTX vs TNGX Comparison April 2026
XRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XRTX stands at 626.6K. In comparison, TNGX has a market cap of 3.1B. Regarding current trading prices, XRTX is priced at $2.91, while TNGX trades at $26.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XRTX currently has a P/E ratio of -0.80, whereas TNGX's P/E ratio is -30.32. In terms of profitability, XRTX's ROE is -1.11%, compared to TNGX's ROE of -0.50%. Regarding short-term risk, XRTX is more volatile compared to TNGX. This indicates potentially higher risk in terms of short-term price fluctuations for XRTX.Check TNGX's competition here
XRTX vs ALMS Comparison April 2026
XRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XRTX stands at 626.6K. In comparison, ALMS has a market cap of 3B. Regarding current trading prices, XRTX is priced at $2.91, while ALMS trades at $25.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XRTX currently has a P/E ratio of -0.80, whereas ALMS's P/E ratio is -8.64. In terms of profitability, XRTX's ROE is -1.11%, compared to ALMS's ROE of -0.73%. Regarding short-term risk, XRTX is more volatile compared to ALMS. This indicates potentially higher risk in terms of short-term price fluctuations for XRTX.Check ALMS's competition here